July 16, 2025 - HighField Bio

July 16, 2025 in Press Release

HighField Biopharmaceuticals Dosed First Patient in Phase 1 Trial of Liposomal T Cell Engager HF50 (TCEplex)

HighField Biopharmaceuticals Dosed First Patient in Phase 1 Trial of Liposomal T Cell Engager HF50 (TCEplex) HF50 is a T cell engager derived from HighField’s unique immunoliposome platforms. A ...

HighField Biopharmaceuticals Dosed First Patient in Phase 1 Trial of Liposomal T Cell Engager HF50 (TCEplex)

ASCO 2025 Abstract: First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer patients: Comparison with ADCs.

AACR 2025 Poster: Myeloid cell targeted immune modulation in solid tumor and brain tumor patients: an analysis of NCTO5388487 phase 1 study data.

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

HighField Biopharmaceuticals Dosed First Patient in Phase 1 Trial of Liposomal T Cell Engager HF50 (TCEplex)